Klinikum Der Landeshauptstadt Stuttgart gKAöR

The clinic’s ophthalmology program focuses on exudative age‑related macular degeneration and acute retinal vascular events such as central retinal artery occlusion. Clinical studies aim to restore visual function by testing innovative surgical approaches and adjunctive pharmacologic agents.

• Vitrectomy combined with subretinal tissue‑plasminogen activator for submacular hemorrhage
• Early reperfusion therapy for acute central retinal artery occlusion
• Evaluation of anti‑VEGF therapy with gas tamponade versus anti‑VEGF monotherapy

Patients benefit from access to cutting‑edge procedures at the Klinikum Der Landeshauptstadt Stuttgart gKAöR while contributing to advances in retinal disease management.

Research in the hematology‑oncology unit addresses a spectrum of lymphoid malignancies, including classical Hodgkin lymphoma, large B‑cell lymphoma, and ALK‑positive anaplastic large‑cell lymphoma. Trials evaluate novel antibody‑drug conjugates, targeted kinase inhibitors, and immunotherapy regimens to improve progression‑free survival.

• Glofitamab plus polatuzumab‑based regimen versus standard chemo
• MK‑4280A compared with physician’s choice chemotherapy in relapsed/refractory Hodgkin lymphoma
• Acalabrutinib added to reduced‑dose CHOP for elderly diffuse large B‑cell lymphoma
• Vinblastine monotherapy for standard‑risk ALK‑positive anaplastic large‑cell lymphoma
• Personalized checkpoint‑inhibition strategy for early‑stage unfavorable Hodgkin lymphoma

The multidisciplinary team of 32 investigators enables rapid enrollment and comprehensive care for patients across Stuttgart and beyond.

The center’s oncology research targets solid and hematologic cancers, with a particular emphasis on aggressive B‑cell lymphomas and central nervous system malignancies such as primary central nervous lymphoma. Studies are designed to test combination regimens that incorporate monoclonal antibodies, small‑molecule inhibitors, and novel chemotherapy backbones.

• Methotrexate‑based MTR² protocol for primary CNS lymphoma unsuitable for intensive therapy
• Combination of acalabrutinib with R‑miniCHOP in older patients with diffuse large B‑cell lymphoma
• Evaluation of checkpoint inhibitor tislelizumab within a PET‑guided first‑line strategy
• Investigation of targeted therapies for high‑grade B‑cell lymphoma with MYC/BCL2 rearrangements

By integrating advanced imaging and molecular profiling, the site strives to personalize treatment and reduce toxicity for patients with high‑risk neoplasms.

Neurology trials at the facility focus on disorders affecting the visual and peripheral nervous systems, notably primary central nervous lymphoma and chemotherapy‑induced peripheral neuropathy. Research aims to enhance disease control while preserving neurological function through innovative drug combinations and supportive care measures.

• MTR² regimen to provide feasible therapy for PCNSL patients unable to tolerate intensive protocols
• Placebo‑controlled study of an herbal oil to lower the incidence of grade II+ chemotherapy‑induced polyneuropathy
• Functional visual recovery assessment after early reperfusion therapy for acute retinal artery occlusion
• Safety and efficacy of targeted agents in CNS‑directed lymphoma treatment

The collaboration between the eye clinic and the neuro‑center enables comprehensive evaluation of both ocular and central nervous outcomes at Klinikum Der Landeshauptstadt Stuttgart.